Search | Clinical Trials Finder

Conditions: Menopause, Depression
Interventions: MDD diagnosis and Estrogen treatment, MDD diagnosis and Fluoxetine treatment, MDD diagnosis with both Estrogen and Fluoxetine treatment, No depression and estrogen treatment; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 40 Years to 70 Years · Female only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2008
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Breast Cancer
Interventions: 6 Gy/ fraction; Radiation
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Atherosclerosis, Chlamydia Infections, Cytomegalovirus Infections, Pneumonia, Bacterial, Postmenopause
Interventions: Estrogen therapy; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Psychological Phenomena and Processes, Nutrition Physiological Phenomena
Interventions: No fiber, Low GI high fiber viscous meal, Low GI high fiber non-viscous; Dietary Supplement
Lead sponsor: Clinical Nutrition Research Center, Illinois Institute of Technology; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2018
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Osteoporosis, Post-menopausal
Interventions: Teriparatide, Zoledronic Acid; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 55 Years to 89 Years · Female only
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 9
States / cities: Lakewood, Colorado • Atlanta, Georgia • Gainesville, Georgia + 6 more

Conditions: Comparing Bioavailability When Makena® is Administered in Healthy Post-menopausal Women
Interventions: Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL); Drug
Lead sponsor: AMAG Pharmaceuticals, Inc.; Industry
Eligibility: 50 Years to 75 Years · Female only
Enrollment: 122 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 5
States / cities: Anaheim, California • DeLand, Florida • Miami, Florida + 2 more

Conditions: Breast Neoplasms
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 50 Years to 69 Years · Female only
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Recurrent Urinary Tract Infection, Postmenopause, Postmenopausal Syndrome, Postmenopausal Symptoms, Menopause
Interventions: Prasterone, Placebo; Drug
Lead sponsor: Olivia Cardenas-Trowers, M.D.; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Metastatic Breast Cancer
Interventions: Dasatinib, Letrozole; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 27
States / cities: Sedona, Arizona • Tucson, Arizona • Denver, Colorado + 22 more

Conditions: Post-menopause
Interventions: Study Procedures; Other
Lead sponsor: Emory University; Other
Eligibility: 45 Years and older · Female only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 4
States / cities: Atlanta, Georgia

Conditions: Cardiovascular Risk Reduction
Interventions: Estradiol 100 Micrograms Patch, Estradiol Patch; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 21 Years to 45 Years · Female only
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Dyspareunia
Interventions: Prasterone; Drug
Lead sponsor: San Diego Sexual Medicine; Other
Eligibility: 21 Years to 80 Years · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: San Diego, California

Conditions: Breast Cancer
Interventions: Bosutinib, Letrozole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 5
States / cities: Whittier, California • Joliet, Illinois • Niles, Illinois + 2 more

Conditions: Advanced Breast Cancer
Interventions: AZD2171, Fulvestrant; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years · Female only
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2016
U.S. locations: 6
States / cities: Burbank, California • Los Angeles, California • Palm Springs, California + 3 more

Conditions: Breast Cancer, Ductal Carcinoma, Estrogen-receptor-positive Breast Cancer, Atypical Lobular Hyperplasia, BRCA2 Mutation, CHEK2 Gene Mutation, Ataxia Telangiectasia Mutated Gene Mutation
Interventions: Exemestane, Tamoxifen; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: Female only
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Osteoporosis
Interventions: Bazedoxifene Acetate, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 55 Years to 80 Years · Female only
Enrollment: 7,609 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2010
U.S. locations: 205
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 141 more

Conditions: Menopause
Interventions: TSEC (Tissue-selective estrogen complexes), Placebo; Drug · Other
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 50 Years to 60 Years · Female only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Obesity, Insulin Resistance, Sedentary Lifestyle
Interventions: Diet modification, Aerobic exercise; Behavioral
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 45 Years to 80 Years · Female only
Enrollment: 103 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2008
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Focus of the Study is Insulin Sensitivity
Interventions: Dietary Fiber; Dietary Supplement
Lead sponsor: Ingredion Incorporated; Industry
Eligibility: 19 Years to 70 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Breast Cancer
Interventions: letrozole; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 50 Years and older · Female only
Enrollment: 261 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 48
States / cities: Huntsville, Alabama • Little Rock, Arkansas • Grass Valley, California + 43 more

Conditions: Vaginal Atrophy
Interventions: IntraGen RF, DiVA, Placebo (DIVA/IntraGen combined); Device
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Dehydration, Menstruation, Pre-menopause, Peri-menopausal Women, Post-menopausal Women, Hydration
Interventions: placebo beverage, electrolyte beverage; Other
Lead sponsor: PepsiCo Global R&D; Industry
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 2
States / cities: Bradenton, Florida • Valhalla, New York

Conditions: Ductal Breast Carcinoma In Situ, Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, Invasive Cribriform Breast Carcinoma, Invasive Ductal Carcinoma, Not Otherwise Specified, Lobular Breast Carcinoma In Situ, Mucinous Breast Carcinoma, Papillary Breast Carcinoma, Progesterone Receptor Positive, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Tubular Breast Carcinoma
Interventions: Therapeutic Conventional Surgery, Radiation Therapy, Laboratory Biomarker Analysis, Quality-of-Life Assessment; Procedure · Radiation · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 50 Years and older · Female only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Breast Cancer
Interventions: Letrozole, Placebo, Taselisib; Drug · Other
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 334 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 8
States / cities: Santa Ana, California • Boston, Massachusetts • Basking Ridge, New Jersey + 5 more

Search by objective public record fields.

Brain Imaging Study in Menopausal Women With and Without Major Depressive Disorder

Safety Study of the Hypo-fractionated (Large Doses) Radiation Therapy in Post-menopausal Women With Breast Cancers

Effects of Hormone Therapy on the Immune Systems of Postmenopausal Women With Chronic Infections

The Effects of Fiber on Appetite and Digestion Hormones

Effects of Teriparatide or Zoledronic Acid Treatment on Bone in Postmenopausal Osteoporotic Women

Comparing Bioavailability When Preservative-free Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) is Administered as an Intramuscular Manual Injection or as a Subcutaneous Injection Using an Auto-injector in Healthy Post-menopausal Women

Intestine Bacteria and Breast Cancer Risk

Clinical Trial on the Preventive Effect of Intravaginal Prasterone on Recurrent Urinary Tract Infections in Postmenopausal Women

Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic

Mental Stress Reactivity in Women With CMD

Oophorectomy, Estrogen Therapy and Cardiovascular Disease Risk in Young Women

Changes to Vulva, Vestibule, Urethral Meatus and Vagina 20 Weeks Post Daily Prasterone in Women With Dyspareunia

Study Evaluating Bosutinib-Letrozole Combination Versus Letrozole Alone In Post Menopausal Women With Breast Cancer

AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.

Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer

Study Evaluating Bazedoxifene Acetate In Osteoporosis In Postmenopausal Women

Raising Insulin Sensitivity in Post Menopause

Race, Menopause and Metabolism After Exercise and Diet

Effects of Dietary Fiber on Insulin Sensitivity

Rheumatological Evaluation of Anastrozole and Letrozole as Adjuvant Treatment in Post-menopausal Women With Breast Cancer

Radiofrequency and Hybrid Fractional Laser for Vaginal Rejuvenation

Hydration & Female Life Stages

Radiation Therapy in Treating Post-Menopausal Women With Early Stage Breast Cancer Undergoing Surgery

A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI)